The U.S. Supreme Court has denied Acorda Therapeutics bid to revive patents on its top-selling multiple sclerosis drug Ampyra. This after biotech industry trade groups had urged the court to take up the case, saying an appeals court ruling that invalidated Acorda’s patents harms incentives to develop new medicines or explore new uses for older drugs. The patents Acorda sought to revive would have barred competition to Ampyra from generic drugs until at least 2025. An earlier patent licensed by the company expired in 2018. The decision was hailed by those who argue that drugmakers tweak their medicines or develop new uses to get a second generation of patent exclusivity in a practice known as “evergreening”. Learn More